The scrutiny follows the company’s August 11, 2026, second-quarter financial report, which revealed that $3.8 million of its $5.5 million total revenue stemmed from one-time licensing milestones rather than core operations. Organic sales for VIZZ stagnated at $1.73 million, reflecting a modest 9% volume growth. The market reaction was immediate; the following day, Bank of America downgraded the stock from "Buy" to "Neutral," slashing its price target from $31.00 to $7.00 due to the lackluster product rollout. Investors who suffered losses are now being urged to contact Danielle Peyton at Pomerantz LLP to discuss potential participation in a class action lawsuit.
Pomerantz Law Firm Probes LENZ Therapeutics Over Financial Disclosures
Pomerantz LLP has launched an investigation into LENZ Therapeutics following a sharp decline in the company’s stock price. The inquiry focuses on potential securities fraud or unlawful business practices, specifically examining whether leadership misled shareholders regarding the commercial performance of their flagship eye drop product, VIZZ.
Comments (0)
No comments yet. Be the first!